AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Compare which total market fund to hold in retirement in 2024 and how to balance it with other assets. Focus on cost, tax efficiency, and diversification.
28,509 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
This international recap dives into how June political headlines and tech softness have weighed on key markets. Learn...
With savings yields retreating as the Fed eases policy, two utility ETFs offer a compelling mix of income and upside....
A major institutional purchase has put Enviri in the spotlight. This article breaks down what the $43 million buy mea...
When headlines warn of a strike and then show diplomacy's glow, oil markets react in real time. This guide outlines s...
When a fintech stock investor trims a large stake in a rising Brazilian payments firm, traders and everyday investors...
Fox stock is down after announcing a Roku deal, leaving investors weighing value vs risk. This guide breaks down the ...
A blue-chip tech giant, strong cash flow, and bold AI bets collide to create a setup where microsoft stock cheap coul...
July could bring a fresh wave of stock gains. This article highlights three stocks likely to lead a rally, with clear...
Palo Alto Networks has seen a meaningful pullback, but a dip can become a doorway for patient investors. This guide b...
When a company's CFO sells stock, investors watch closely. This analysis dives into Commvault Systems' sold over trad...
A blockbuster year for Delek US Holdings brought attention to a notable insider move. The event described as delek in...